Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc
Oric Pharmicals宣布在针对突变非小细胞肺癌患者的Oric-114的1B期试验中,三个扩展队列中首批患者给药
Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc
Oric Pharmicals宣布在针对突变非小细胞肺癌患者的Oric-114的1B期试验中,三个扩展队列中首批患者给药
使用浏览器的分享功能,分享给你的好友吧